Treating bipolar disorder: Evidence-based guidelines for family medicine

Canadian Family Physician

Volumn 50, Issue MAR., 2004, Pages 388-394

  McIntyre, Roger S ^a   Mancini, Deborah A ^b   Lin, Peter ^b   Jordan, John ^b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; FLUOXETINE; GABAPENTIN; HALOPERIDOL; LAMOTRIGINE; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE; VALPROATE SEMISODIUM; VENLAFAXINE;

ARTICLE; BIPOLAR DISORDER; BIPOLAR MANIA; BODY WEIGHT DISORDER; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL STUDY; DEPRESSION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG TOLERABILITY; DYSLIPIDEMIA; DYSPHORIA; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; FAMILY MEDICINE; HUMAN; MEDLINE; MOOD; PRACTICE GUIDELINE; QUALITY CONTROL; SOMNOLENCE; STEVENS JOHNSON SYNDROME; TARDIVE DYSKINESIA; WEIGHT GAIN;

ALGORITHMS; ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DRUG THERAPY, COMBINATION; FAMILY PRACTICE; HUMANS; LITHIUM; PRACTICE GUIDELINES;

EID: 1642404390     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Piver A, Yatham LN, Lam RW. Bipolar spectrum disorders. New perspectives. Can Fam Physician 2002;48:896-904.
2. Hirschfeld RM, Holzer C, Calabrese JR, Weissman M, Reed M, Davies M, et al. Validity of the mood disorder questionnaire: A general population study. Am J Psychiatry 2003;160: 178-80.
3. Hirschfeld RM, Calabrese JR, Weissamn MM, Reed M, Davies MA, Frye MA, et al. Screening for bipolar disorder in the community. J Clin Psychiatry 2003;64(1):53-9.
4. Tondo L, Baldessarini RJ. Reduced suicide risk during lithium maintenance treatment. J Clin Psychiatry 2000;61(Suppl 9):97-104.
5. Goodwin F, Jamison K. Manic-depressive illness. New York, NY: Oxford University Press; 1990.
6. Akiskal HS, Bourgeois ML, Angst J, Post R, Moller H, Hirschfeld R. Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders. J Affect Disord 2000;59(Suppl 1);S5-S30.
7. Kessing LV, Andersen PK, Mortensen PB. Predictors of recurrence in affective disorder. A case register study. J Affect Disord 1998;49(2):101-8.
8. Lopez AD, Murray CC. The global burden of disease, 1990-2020. Nat Med 1998;4(11): 1241-3.
9. Rothenberg A. Bipolar illness, creativity, and treatment. Psychiatr Q 2001;72(2):131-47.
10. Manning JS, Haykal RF, Connor PD, Akiskal HS. On the nature of depressive and anxious states in a family practice setting: The high prevalence of bipolar II and related disorders in a cohort followed longitudinally. Compr Psychiatry 1997;38(2):102-8.
11. Ghaemi SN, Sachs GS, Chiou AM, Pandurangi AK, Goodwin K. Is bipolar disorder still underdiagnosed? Are antidepressants overutilized? J Affect Disord 1999;52(1-3):135-44.
12. Hirschfeld RM, Williams JB, Spitzer RL, Calabrese JR, Flynn L, Keck PE Jr, et al. Development and validation of a screening instrument for bipolar spectrum disorder: The Mood Disorder Questionnaire. Am J Psychiatry 2000;157:1873-5.
13. American Psychiatric Association. Diagnostic and statistical manual for mental disorders. 4th edition. Washington, DC: American Psychiatric Association; 1994.
14. Lish JD, Dime-Meenan S, Whybrow PC, Price RA, Hirschfeld RM.The National Depressive and Manic-depressive Association (DMDA) survey of bipolar members. J Affect Disord 1994;31(4):281-94.
15. Tondo L, Hennen J, Baldessarini RJ. Lower suicide risk with long-term lithium treatment in major affective illness: A meta-analysis. Acta Psychiatr Scand 2001;104(3):163-72.
16. Tondo L, Baldessarini RJ, Hennen J, Minnai GP, Salis P, Scamonatti L, et al. Suicide attempts in major affective disorder patients with comorbid substance use disorders. J Clin Psychiatry 1999;60(Suppl 2):63-9; discussion 75-6, 113-6.
17. Ghaemi SN. On defining mood stabilizer. Bipolar Disord 2001;3:154-8.
18. Baldessarini RJ, Tondo L, Hennen J. Treating the suicidal patient with bipolar disorder. Reducing suicide risk with lithium. Ann N Y Acad Sci 2001;932:24-38; discussion 39-43.
19. Calabrese JR, Woyshville MJ. Lithium therapy: Limitations and alternatives in the treatment of bipolar disorders. Ann Clin Psychiatry 1995;7(2):103-12.
20. Maj M, Pirozzi R, Magliano L. Nonresponse to reinstituted lithium prophylaxis in previously responsive bipolar patients: Prevalence and predictors. Am J Psychiatry 1995;152:1810-1.
21. De Leon O. Antiepileptic drugs for the acute and maintenance treatment of bipolar disorder. Harvard Rev Psychiatry 2001;9(5):209-22.
22. Bowden CL. Novel treatments for bipolar disorder. Expert Opin Investig Drugs 2001;10(4): 661-71.
23. Zerjav-Lacombe S, Tabarsi E. Lamotrigine: A review of clinical studies in bipolar disorders. Can J Psychiatry 2001;46(4):328-33.
24. Pande AC, Crockatt JG, Janney CA, Werth JL, Tsaroucha G. Gabapentin in bipolar disorder: A placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. Bipolar Disord 2000;2(3 Pt 2):249-55.
25. Maidment ID. Gabapentin treatment for bipolar disorders. Ann Pharmacother 2001;35(10): 1264-9.
26. McIntyre RS, Mancini DA, McCann S, Srinivasan J, Sagman D, Kennedy SH. Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: A preliminary single-blind study. Bipolar Disord 2002;4:207-13.
27. VanKammen D. The efficacy of topiramate in acute bipolar mania. Montreal, Que: Collegium Internationale Neuro-Psychopharmacologicum; 2002.
28. Ramasubbu R. Dose-response relationship of selective serotonin reuptake inhibitors treatment-emergent hypomania in depressive disorders. Acta Psychiatr Scand 2001;104(3):236-8; discussion 238-9.
29. Siris SG. Depression in schizophrenia: Perspective in the era of ΑaTypical" antipsychotic agents. Am J Psychiatry 2000;157(9):1379-89.
30. Tollefson GD, Andersen SW. Should we consider mood disturbance in schizophrenia as an important determinant of quality of life? J Clin Psychiatry 1999;60(Suppl 5):23-9; discussion 30.
31. Yassa R, Ghadirian AM, Schwartz G. Prevalence of tardive dyskinesia in affective disorder patients. J Clin Psychiatry 1983;44:410-2.
32. Ghaemi SN, Cherry EL, Katzow JA, Goodwin FK. Does olanzapine have antidepressant properties? A retrospective preliminary study. Bipolar Disord 2000;2(3 Pt 1):196-9.
33. Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 2001;158: 765-74.
34. Ostroff RB, Nelson JC. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry 1999;60:256-9.
35. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C Jr, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17(5):407-18.
36. Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001;158:131-4.
37. Kennedy SH, Lam RW, Cohen NL, Ravindran AV. Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments. Can J Psychiatry 2001;46(Suppl 1):38S-58S.
38. Sachs GS, Grossman F, Ghaemi SN, Okamoto A, Bowden CL. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: A double-blind, placebo controlled comparison of efficacy and safety. Am J Psychiatry 2002;159;1146-54.
39. McIntyre R, Mancini D, McCann S, Srinivasan J, Kennedy S. The antidepressant effects of risperidone and olanzapine in bipolar disorder. Can J Clin Psychopharmacol. In press.
40. Tohen M. The efficacy of olanzapine combination fluoxetine or their combination in bipolar depression. Philadelphia, Pa: American Psychiatric Association Annual Meeting. 2002.
41. Keck PE Jr, Wilson DR, Strakowski SM, McElroy SL, Kizer DL, Balistreri TM, et al. Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders. J Clin Psychiatry 1995;56:466-70.
42. Tohen M, Jacobs TG, Feldman PD. Onset of action of antipsychotics in the treatment of mania. Bipolar Disord 2000;2(3 Pt 2):261-8.
43. McIntyre R, McCann SM, Kennedy SH. Antipsychotic metabolic effects: Weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry 2001;46(3):273-81.
44. Hummel B, Walden J, Stampfer R, Dittmann S, Amann B, Sterr A, et al. Acute antimanic efficacy and safety of oxcarbazepine in an open trial with an on-off-on design. Bipolar Disord 2002;4:412-7.
45. Howland RH. Induction of mania with serotonin reuptake inhibitors. J Clin Psychopharmacol 1996;16(6):425-7.
46. Gray SM, Otto MW. Psychosocial approaches to suicide prevention: Applications to patients with bipolar disorder. J Clin Psychiatry 2001;62(Suppl 25):56-64.
47. Malkoff-Schwartz S, Frank E, Anderson BP, Hlastala SA, Luther JF, Sherrill JT, et al. Social rhythm disruption and stressful life events in the onset of bipolar and unipolar episodes. Psychol Med 2000;30(5):1005-16.